Novo Nordisk A/S (NYSE:NVO) Shares Bought by MONECO Advisors LLC

MONECO Advisors LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 19.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,359 shares of the company’s stock after buying an additional 385 shares during the period. MONECO Advisors LLC’s holdings in Novo Nordisk A/S were worth $203,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. Autumn Glory Partners LLC raised its stake in Novo Nordisk A/S by 39.9% in the third quarter. Autumn Glory Partners LLC now owns 22,671 shares of the company’s stock valued at $2,699,000 after buying an additional 6,463 shares in the last quarter. Old Port Advisors raised its stake in Novo Nordisk A/S by 4.8% in the third quarter. Old Port Advisors now owns 5,094 shares of the company’s stock valued at $607,000 after buying an additional 233 shares in the last quarter. Traynor Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 3.4% during the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock worth $36,364,000 after purchasing an additional 10,019 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Novo Nordisk A/S by 5.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,000 shares of the company’s stock worth $2,500,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Fidelis Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 107.0% during the third quarter. Fidelis Capital Partners LLC now owns 20,313 shares of the company’s stock worth $2,351,000 after purchasing an additional 10,500 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the topic of a number of research analyst reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $90.94 on Wednesday. The stock has a market capitalization of $408.07 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15. The stock’s 50-day moving average price is $85.32 and its 200 day moving average price is $107.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.